Drug Toxicity Clinical Trial
Official title:
Evaluation of Drug Overdose Poisoning Cases and Indications for ICU Admission
1. Evaluation of drug overdose cases presented to Assiut university hospitals' adults and pediatric emergency departments (EDs) in one year period. 2. Evaluation the role of intensive care unit (ICU) admission in these cases and possible scoring system for common groups of drug overdose.
Poisoning is a medical emergency representing a health problem all over the world with an incidence rate that is variable from one place to another. The nature of poison used varies in different parts of the world and may vary even in different parts of the same country. The pattern of poisoning within a country depends on several factors such as the accessibility of various poisons, socio-economic status of the population, religious and cultural influences and drug prescription manners. Drug overdose continues to be the most common cause of acute poisoning all over the world. An estimated 2 to 5 million poisonings and drug overdoses occur annually in the United States of America. Overdose is the most common manifestation of deliberate self-harm behavior, and is a common cause of presentation to hospital Emergency Departments (EDs). It starts to get global attention due to its higher rate of morbidity and mortality in spite of being a preventable cause of death. Acute drug overdosing is an important cause of organ dysfunction and metabolic derangements and the patients often require intensive care admission. Among patients admitted to hospital following drug overdoses, approximately 13-22% will require Intensive Care Unit (ICU) admission. Overdoses have been reported to account for 3.8-13.8% of all ICU admissions with 79.5-84% requiring mechanical ventilation in Australia. The treatment and complications of patients with acute drug intoxication in ICU vary according the nature of the substance ingested, individual amount of drug, and the concomitant use of other substances. The interventions requiring critical care in acute drug-poisoned patients include the need for airways protection and mechanical ventilation, hemodynamic stabilization and needs for vasopressors, and specific procedures that would enhance the clearance of the toxins involved. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04696081 -
Atrial Fibrillation in Active Cancer Patients
|
||
Active, not recruiting |
NCT03651778 -
GHB Poisoning and Poisoning Induced by Others
|
||
Completed |
NCT04120233 -
MW151-101: First-in-human Study of MW151
|
Phase 1 | |
Recruiting |
NCT01965275 -
High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs
|
Phase 2 | |
Completed |
NCT01614080 -
Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA
|
N/A | |
Recruiting |
NCT04659343 -
TDM for Optimized Outcome in Patients With mRCC.
|
||
Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
Completed |
NCT01135680 -
Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100
|
Phase 1 | |
Completed |
NCT03947034 -
Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)
|
||
Recruiting |
NCT03885388 -
Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma (GTN) Patients With Score of 5-6
|
Phase 2/Phase 3 | |
Completed |
NCT00491595 -
Phase I Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women
|
Phase 1 | |
Recruiting |
NCT03469063 -
Impact of AferBio® on Quality of Life and Chemotherapy Toxicity in Lung Cancer Patients
|
N/A | |
Not yet recruiting |
NCT04671589 -
Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.
|
Phase 4 | |
Completed |
NCT03280368 -
Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
|
||
Withdrawn |
NCT01374061 -
Pre Hospital Evaluation of Video Laryngoscopy
|
Phase 4 | |
Completed |
NCT03994302 -
Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)
|
||
Completed |
NCT03392311 -
Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Terminated |
NCT00090844 -
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
|
Phase 2 | |
Terminated |
NCT00213642 -
Tc-99m Renography and Cisplatin-induced Nephrotoxicity
|
N/A |